Cipher Pharmaceuticals Inc. (TSE:CPH - Get Free Report) NASDAQ: CPHR shares passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of C$14.44 and traded as low as C$13.40. Cipher Pharmaceuticals shares last traded at C$13.74, with a volume of 34,029 shares.
Analyst Ratings Changes
Separately, Stifel Nicolaus reduced their target price on shares of Cipher Pharmaceuticals from C$19.00 to C$17.00 in a report on Monday, November 11th.
Get Our Latest Stock Report on CPH
Cipher Pharmaceuticals Trading Down 0.2 %
The company has a debt-to-equity ratio of 0.33, a current ratio of 11.18 and a quick ratio of 2.67. The stock has a 50-day moving average price of C$14.34 and a two-hundred day moving average price of C$14.78. The stock has a market cap of C$340.35 million, a PE ratio of 10.64 and a beta of 1.20.
Cipher Pharmaceuticals (TSE:CPH - Get Free Report) NASDAQ: CPHR last released its quarterly earnings data on Thursday, November 7th. The company reported C$0.01 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of C$0.03 by C($0.02). The firm had revenue of C$14.15 million during the quarter, compared to the consensus estimate of C$13.37 million. Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%. Sell-side analysts forecast that Cipher Pharmaceuticals Inc. will post 1.2907348 earnings per share for the current fiscal year.
Cipher Pharmaceuticals Company Profile
(
Get Free Report)
Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.
See Also
Before you consider Cipher Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cipher Pharmaceuticals wasn't on the list.
While Cipher Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
